Exact Mass: 755.5829
Exact Mass Matches: 755.5829
Found 500 metabolites which its exact mass value is equals to given mass value 755.5829,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(16:0/18:3)
PC(16:0/18:3(9Z,12Z,15Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of a-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(16:1(9Z)/18:2(9Z,12Z))
PC(16:1(9Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(14:0/20:3(5Z,8Z,11Z))
PC(14:0/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:0/20:3(5Z,8Z,11Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of mead acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(14:0/20:3(8Z,11Z,14Z))
PC(14:0/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(14:0/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(14:1(9Z)/20:2(11Z,14Z))
PC(14:1(9Z)/20:2(11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:1(9Z)/20:2(11Z,14Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(16:0/18:3(6Z,9Z,12Z))
PC(16:0/18:3(6Z,9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of g-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(18:2(9Z,12Z)/16:1(9Z))
PC(18:2(9Z,12Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/16:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(18:3(6Z,9Z,12Z)/16:0)
PC(18:3(6Z,9Z,12Z)/16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(6Z,9Z,12Z)/16:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(18:3(6Z,9Z,12Z)/16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(6Z,9Z,12Z)/16:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(18:3(9Z,12Z,15Z)/16:0)
PC(18:3(9Z,12Z,15Z)/16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(9Z,12Z,15Z)/16:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(20:2(11Z,14Z)/14:1(9Z))
PC(20:2(11Z,14Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:2(11Z,14Z)/14:1(9Z)), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(20:2(11Z,14Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:2(11Z,14Z)/14:1(9Z)), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(20:3(5Z,8Z,11Z)/14:0)
PC(20:3(5Z,8Z,11Z)/14:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(5Z,8Z,11Z)/14:0), in particular, consists of one chain of mead acid at the C-1 position and one chain of myristic acid at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the myristic acid moiety is derived from nutmeg and butter. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(20:3(5Z,8Z,11Z)/14:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(5Z,8Z,11Z)/14:0), in particular, consists of one chain of mead acid at the C-1 position and one chain of myristic acid at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the myristic acid moiety is derived from nutmeg and butter. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:1(11Z)/P-18:1(11Z))
PE(20:1(11Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:1(11Z)/P-18:1(11Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The eicosenoic acid moiety is derived from vegetable oils and cod oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(20:1(11Z)/P-18:1(9Z))
PE(20:1(11Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:1(11Z)/P-18:1(9Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The eicosenoic acid moiety is derived from vegetable oils and cod oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:1(11Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:1(11Z)/P-18:1(9Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The eicosenoic acid moiety is derived from vegetable oils and cod oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:2(11Z,14Z)/P-18:0)
PE(20:2(11Z,14Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:2(11Z,14Z)/P-18:0), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicosadienoic acid moiety is derived from fish oils and liver, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(22:2(13Z,16Z)/P-16:0)
PE(22:2(13Z,16Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(22:2(13Z,16Z)/P-16:0), in particular, consists of one chain of docosadienoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The docosadienoic acid moiety is derived from animal fats, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:0/P-18:1(11Z))
PC(P-18:0/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/P-18:1(11Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/P-18:1(9Z))
PC(P-18:0/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/P-18:1(9Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(11Z)/P-18:0)
PC(P-18:1(11Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/P-18:0), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(9Z)/P-18:0)
PC(P-18:1(9Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/P-18:0), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-16:0/22:2(13Z,16Z))
PE(P-16:0/22:2(13Z,16Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:2(13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of docosadienoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the docosadienoic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/22:2(13Z,16Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:2(13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of docosadienoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the docosadienoic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:0/20:2(11Z,14Z))
PE(P-18:0/20:2(11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:2(11Z,14Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/20:2(11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:2(11Z,14Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicosadienoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicosadienoic acid moiety is derived from fish oils and liver. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(11Z)/20:1(11Z))
PE(P-18:1(11Z)/20:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:1(11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of eicosenoic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/20:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:1(11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of eicosenoic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(9Z)/20:1(11Z))
PE(P-18:1(9Z)/20:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(dm18:1(9Z)/20:1(11Z)), in particular, consists of one chain of plasmalogen 18:P-9 at the C-1 position and one chain of eicosenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/20:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(dm18:1(9Z)/20:1(11Z)), in particular, consists of one chain of plasmalogen 18:P-9 at the C-1 position and one chain of eicosenoic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the eicosenoic acid moiety is derived from vegetable oils and cod oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
1-O-beta-D-Galactopyranosyl-N-(2R-hydroxy-15-methylpalmitoyl)-9,17-dimethylsphinga-4E,8E-dienin
GlcCer(d15:2(4E,6E)/22:0(2OH))
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(2S,3R,4E,14Z)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (Z)-icos-11-enoate
[2-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]hexacos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxyicosanoylamino)tetracosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxynonadecanoylamino)pentacosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)octadeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]docos-4-ene-1-sulfonic acid
3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]tetracosane-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxyoctadecanoylamino)hexacosa-4,8-diene-1-sulfonic acid
3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]hexacosane-1-sulfonic acid
3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]octadecane-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]henicos-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]nonadec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]icos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxydocosanoylamino)docosa-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]tricos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)nonadeca-4,8-diene-1-sulfonic acid
3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]icosane-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]pentacos-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]octadec-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxytricosanoylamino)henicosa-4,8-diene-1-sulfonic acid
3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]docosane-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]tetracos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxyhenicosanoylamino)tricosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)icosa-4,8-diene-1-sulfonic acid
[3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-heptanoyloxy-3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
(4E,8E,12E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxyicosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
(E)-2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxyicos-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propan-2-yl] (Z)-tetradec-9-enoate
(4E,8E)-2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxyicosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (14Z,17Z,20Z)-octacosa-14,17,20-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
(4E,8E,12E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxytetracosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]docosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] docosanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-docos-13-enoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (Z)-henicos-11-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (Z)-octadec-9-enoate
(4E,8E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxytetracosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-docosoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propan-2-yl] tetradecanoate
(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]docosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (Z)-heptadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (10Z,13Z,16Z)-tetracosa-10,13,16-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (Z)-hexadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]propan-2-yl] dodecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]propan-2-yl] decanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (12Z,15Z,18Z)-hexacosa-12,15,18-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (Z)-nonadec-9-enoate
[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(Z)-nonadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-heptadec-9-enoxy]-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-hexadec-9-enoyl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-nonadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-nonadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-heptadecoxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[4-[3-[(Z)-henicos-11-enoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
4-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2,3-bis[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[3-[(Z)-hexadec-9-enoxy]-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-[(Z)-nonadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[2-[(Z)-heptadec-9-enoyl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] hexadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (13Z,16Z)-tetracosa-13,16-dienoate
[2-heptadecanoyloxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (Z)-docos-13-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] icosanoate
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] octadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (24Z,27Z,30Z)-octatriaconta-24,27,30-trienoate
[(E,2S,3R)-2-[[(E)-hexacos-17-enoyl]amino]-3-hydroxyoctadec-4-enyl] dihydrogen phosphate
4-[3-dodecanoyloxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-heptadec-7-enoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(11E,14E)-icosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-icos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(10E,12E)-octadeca-10,12-dienoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dodec-5-enoyl]oxy-3-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(14E,17E,20E,23E)-hexacosa-14,17,20,23-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dec-4-enoyl]oxy-2-[(11E,14E,17E,20E,23E)-hexacosa-11,14,17,20,23-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(14E,17E,20E,23E)-hexacosa-14,17,20,23-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dec-4-enoyl]oxy-3-[(11E,14E,17E,20E,23E)-hexacosa-11,14,17,20,23-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,14E)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (6E,9E)-octadeca-6,9-dienoate
4-[3-[(8E,11E,14E,17E,20E)-tricosa-8,11,14,17,20-pentaenoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(10E,13E,16E,19E,22E)-pentacosa-10,13,16,19,22-pentaenoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(9E,12E,15E,18E)-tetracosa-9,12,15,18-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(10E,13E,16E,19E,22E)-pentacosa-10,13,16,19,22-pentaenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (11E,14E)-icosa-11,14-dienoate
4-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(E)-icos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-2-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E)-henicosa-9,11,13-trienoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(11E,14E)-icosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E)-henicosa-9,11,13-trienoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dodec-5-enoyl]oxy-2-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,10E,13E,16E,19E,22E)-pentacosa-7,10,13,16,19,22-hexaenoyl]oxy-3-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(2S,3R,4E,6E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxyhexadeca-4,6-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (5E,8E)-icosa-5,8-dienoate
4-[3-[(10E,12E)-octadeca-10,12-dienoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,6E)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]tetradeca-4,6-dienoxy]phosphoryl]oxyethyl-trimethylazanium
4-[2-[(5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (13E,16E)-docosa-13,16-dienoate
4-[2-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
4-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(15E,18E,21E)-tetracosa-15,18,21-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
4-[3-[(E)-heptadec-7-enoyl]oxy-2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-dodecanoyloxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
4-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(9E,12E,15E,18E)-tetracosa-9,12,15,18-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (9E,11E)-octadeca-9,11-dienoate
2-[[(2S,3R,4E,8E)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
4-[2,3-bis[[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-hexadec-7-enoyl]oxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (9E,12E)-octadeca-9,12-dienoate
4-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(15E,18E,21E)-tetracosa-15,18,21-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,10E,13E,16E,19E,22E)-pentacosa-7,10,13,16,19,22-hexaenoyl]oxy-2-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-hexadec-7-enoyl]oxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-2-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]icos-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
4-[2-[(8E,11E,14E,17E,20E)-tricosa-8,11,14,17,20-pentaenoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-decanoyloxy-2-[(8E,11E,14E,17E,20E,23E)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(2S,3R,4E,8E)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
4-[2-hexadecanoyloxy-3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (2E,4E)-octadeca-2,4-dienoate
4-[3-[(5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoyl]oxy-2-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-decanoyloxy-3-[(8E,11E,14E,17E,20E,23E)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(2S,3R,4E,8E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tetracosanoylamino)tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(hexadecanoylamino)-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(henicosanoylamino)-3-hydroxyheptadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]pentacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]tetracosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxyhexacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-11-enoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(heptadecanoylamino)-3-hydroxyhenicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(18Z,21Z)-tetracosa-18,21-dienoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octadecanoylamino)icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonadecanoylamino)nonadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentadecanoylamino)tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)pentacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tricosanoylamino)pentadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tetradecanoylamino)tetracosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(docosanoylamino)-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tricos-11-enoyl]amino]pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxyhexacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(icosanoylamino)octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentanoylamino)tritriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(heptanoylamino)-3-hydroxyhentriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(16Z,19Z,22Z)-triaconta-16,19,22-trienoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]pentacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(8E,12E)-3,4-dihydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]octadeca-8,12-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(17Z,20Z)-octacosa-17,20-dienoyl]amino]dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonanoylamino)nonacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octanoylamino)triaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-acetamido-3-hydroxyhexatriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(19Z,22Z)-triaconta-19,22-dienoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(propanoylamino)pentatriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(hexanoylamino)-3-hydroxydotriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(8E,12E,16E)-3,4-dihydroxy-2-[[(Z)-nonadec-9-enoyl]amino]octadeca-8,12,16-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(butanoylamino)-3-hydroxytetratriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(decanoylamino)-3-hydroxyoctacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]icosoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)heptacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydocosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
N-(2-hydroxy-octadecanoyl)-1-beta-glucosyl-9-methyl-sphinga-4E,8E-dienine
N-hexacosanoylsphingosine 1-phosphate(2-)
A ceramide 1-phosphate(2-) in which the N-acyl group is specified as hexacosanoyl.
MePC(34:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(37:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(36:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
